Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,055 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
Kato K, Doki Y, Ogata T, Motoyama S, Kawakami H, Ueno M, Kojima T, Shirakawa Y, Okada M, Ishihara R, Kubota Y, Amaya-Chanaga C, Chen T, Matsumura Y, Kitagawa Y. Kato K, et al. Among authors: ogata t. Esophagus. 2023 Apr;20(2):291-301. doi: 10.1007/s10388-022-00970-1. Epub 2022 Nov 19. Esophagus. 2023. PMID: 36401133 Free PMC article. Clinical Trial.
First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study.
Kato K, Kojima T, Hara H, Tsuji A, Yasui H, Muro K, Satoh T, Ogata T, Ishihara R, Goto M, Baba H, Nishina T, Han S, Iwakami K, Yatsuzuka N, Doi T. Kato K, et al. Among authors: ogata t. Esophagus. 2024 Apr 12. doi: 10.1007/s10388-024-01053-z. Online ahead of print. Esophagus. 2024. PMID: 38607538
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.
Kato K, Doki Y, Chau I, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Makino T, Blum Murphy M, Amaya-Chanaga C, Patel A, Hu N, Matsumura Y, Kitagawa Y, Ajani J. Kato K, et al. Among authors: ogata t. Cancer Med. 2024 May;13(9):e7235. doi: 10.1002/cam4.7235. Cancer Med. 2024. PMID: 38716626 Free PMC article. Clinical Trial.
Comparison of Survival Between ypStage and pStage in Gastric Cancer.
Komori K, Yamada T, Ando S, Hashimoto I, Watanabe H, Maezawa Y, Fujikawa H, Sawazaki S, Numata M, Aoyama T, Yukawa N, Rino Y, Saito A, Ogata T, Oshima T. Komori K, et al. Among authors: ogata t. Anticancer Res. 2024 Jun;44(6):2661-2670. doi: 10.21873/anticanres.17073. Anticancer Res. 2024. PMID: 38821586
A propensity‑matched analysis of the prognostic value of advanced lung cancer inflammation index in patients with gastric cancer after curative resection.
Hashimoto I, Tanabe M, Onuma S, Morita J, Nagasawa S, Maezawa Y, Kanematsu K, Aoyama T, Yamada T, Ogata T, Yukawa N, Rino Y, Saito A, Oshima T. Hashimoto I, et al. Among authors: ogata t. Oncol Lett. 2024 Apr 26;27(6):285. doi: 10.3892/ol.2024.14418. eCollection 2024 Jun. Oncol Lett. 2024. PMID: 38736744 Free PMC article.
Pathophysiological Implications of Protein Lactylation in Pancreatic Epithelial Tumors.
Takata T, Nakamura A, Yasuda H, Miyake H, Sogame Y, Sawai Y, Hayakawa M, Mochizuki K, Nakao R, Ogata T, Ikoma H, Konishi E, Harada Y, Otsuji E, Itoh Y, Tanaka H. Takata T, et al. Among authors: ogata t. Acta Histochem Cytochem. 2024 Apr 25;57(2):57-66. doi: 10.1267/ahc.24-00010. Epub 2024 Apr 4. Acta Histochem Cytochem. 2024. PMID: 38695038 Free PMC article.
2,055 results